Sunday , May 31 2020
Home / Top Tech / LinkedIn / Amarin’s Vascepa loses one more shield with Hikma’s generic approval

Amarin’s Vascepa loses one more shield with Hikma’s generic approval

After Amarin suffered a surprise patent loss for its key drug Vascepa, the company is appealing and generics makers are hoping their arguments hold. Now, one of them has an FDA go-ahead to launch. 

Hikma on Friday scored an FDA green light for its generic of Vascepa, a fish-oil derivative approved to cut cardiovascular risks in certain high-risk patients. The generics company was one of the drugmakers that challenged Amarin’s patents in Nevada federal court and prevailed.

In late March, that federal court struck down…

Read More – Original Source

Check Also

Read the full text of Jeff Weiner’s parting note on his last day as LinkedIn CEO

Jeff Weiner has stepped down as the Chief Executive Officer (CEO) of LinkedIn. It was announced …

Leave a Reply

Your email address will not be published. Required fields are marked *